Patricia Inácio, PhD,  science writer—

Spanish patients with hereditary angioedema reported fewer severe attacks and longer delays for treatment with Firazyr (icatibant injection) compared with patients from other countries, a retrospective analysis shows. Patients in Spain also reported longer‐lasting attacks. Overall, these findings from the Icatibant Outcome Survey highlight differences in disease management…

Favipiravir, an antiviral medication used to treat influenza and, more recently, COVID-19, may trigger angioedema in some individuals, a case study says. The report was published as a clinical commentary, titled “Angioedema After Favip[i]ravir Treatment: Two cases,” in the Journal of Cosmetic Dermatology. Angioedema, a condition characterized…

The burden that hereditary angioedema (HAE) has on patients’ quality of life is seldom discussed during clinical visits, a U.S. study suggests. The study also found that patients fail to fully describe disease symptoms during such appointments, so their struggles are not well-documented. Therefore, researchers recommend a more patient-driven…

A new mutation in the SERPING1 gene linked to hereditary angioedema (HAE) type 1 was identified in three of five members of a Spanish family. Results were published in a letter to the editor of the journal Pediatric Allergy and Immunology titled “Hereditary angioedema caused by a novel intronic variant of SERPING1.” HAE is a form of…

Swelling attacks affecting the airway usually occur in hereditary angioedema patients between the ages of 20 and 30 — and are more frequent among smokers, a study shows. However, the frequency of attacks was higher in people with acquired angioedema, a type of the chronic disorder in which…

Switching from under-the-skin injections to oral pills of Orladeyo (berotralstat), a preventive treatment, can be done without the need to taper prior therapy or go through complex regimens, according to a case study of a patient and her mother, both of whom have hereditary angioedema (HAE). The report,…

Over a third of hereditary angioedema patients continue to experience an unpredictable rate of annual attacks, including those on long-term preventive therapy, a retrospective analysis shows. These findings highlight the variability of the disease and support the need for constant vigilance by patients and their doctors. The study, “…

Patients with hereditary angioedema (HAE) are willing to try new therapies that can effectively lessen disease burden with less frequent dosing, according to an interview-based study conducted by Astria Therapeutics. The findings were shared in a poster, titled “Burdens of Disease and Treatment in Hereditary…

Adalvo has completed a mandatory requirement for a marketing authorization in the European Union for its generic version of Firazyr (icatibant injection), which is approved for acute attacks in adults with hereditary angioedema (HAE), the company has announced. The successful closure of the decentralized procedure came more…

The Israeli Ministry of Health has agreed to review, under an accelerated process, a marketing application for Orladeyo (berotralstat), BioCryst Pharmaceuticals’ oral preventive treatment for hereditary angioedema (HAE) attacks, in patients 12 and older. Neopharm Israel, one of the leading pharmaceutical companies in Israel, will distribute Orladeyo,…